Brokerage firm UBS Maintains its rating on Laboratory Corp. of America Holdings(NYSE:LH). In a research note issued to the investors, the brokerage major Raises the price-target to $137.50 per share. The shares have been rated Neutral. The rating by UBS was issued on Jul 28, 2016.
Laboratory Corp. of America Holdings (LH) shares turned negative on Thursdays trading session with the shares closing down -0.04 points or -0.03% at a volume of 9,30,967. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $140.81. The peak price level was also seen at $140.81 while the days lowest was $139.58. Finally the shares closed at $140.09. The 52-week high of the shares is $140.81 while the 52-week low is $97.79. According to the latest information available, the market cap of the company is $14,331 M.
Laboratory Corp. of America Holdings(LH) last announced its earnings results on Jul 27, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.38B. Analysts had an estimated revenue of $2.33B. Earnings per share were $2.31. Analysts had estimated an EPS of $2.29.
Several Insider Transactions has been reported to the SEC. On Jun 15, 2016, David P King (President & CEO) sold 196,400 shares at $128.42 per share price.Also, On May 13, 2016, Lisa J Uthgenannt (Chief Human Resources Officer) sold 3,740 shares at $125.17 per share price.On Apr 29, 2016, Edward T Dodson (Principal Accounting Officer) sold 9,392 shares at $126.42 per share price, according to the Form-4 filing with the securities and exchange commission.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.